Send us a message with this link, we would love to hear from you. Standard message rates may apply.

This week, we're discussing a significant development in the treatment of obstructive sleep apnea (OSA). The FDA has recently approved Zepbound, a medication used in combination with diet and exercise, as the first drug option for moderate to severe OSA in adults with obesity. We'll break down how Zepbound works by targeting hormones that reduce appetite, which leads to weight loss, and how this can improve OSA symptoms. We'll also explore the details of the clinical trials that led to this approval, including how they measured the medication's effectiveness and what potential side effects patients should be aware of.

Support the show

Production and Content: Edward Delesky, MD & Nicole Aruffo, RN
Artwork: Olivia Pawlowski

Send us a message with this link, we would love to hear from you. Standard message rates may apply.

Join us as we demystify insulin treatment for type 2 diabetes! We'll break down the different types of insulin, how they work, and when you might need to start them. We'll also cover practical tips for injecting insulin, factors that affect its effectiveness, and how to handle special situations like eating out and travel. This episode is packed with essential information to empower you to manage your type 2 diabetes and live a healthier life!

Support the show

Production and Content: Edward Delesky, MD & Nicole Aruffo, RN
Artwork: Olivia Pawlowski

Send us a message with this link, we would love to hear from you. Standard message rates may apply.

This episode explores the science behind flatulence odor and introduces a simple, over-the-counter remedy: Pepto-Bismol. The episode explains that the unpleasant odor associated with flatulence is primarily caused by hydrogen sulfide (H2S), a gas produced in the colon during the breakdown of food. Pepto-Bismol, or bismuth subsalicylate, works by binding to hydrogen sulfide in the colon and reducing the amount of gas released. The episode highlights a study published in Gastroenterology which found that bismuth subsalicylate significantly reduced H2S release in human fecal samples. Participants in the study experienced a greater than 95% reduction in fecal H2S release after taking Pepto-Bismol for 3-7 days. The episode also emphasizes the importance of consulting a doctor before using Pepto-Bismol, especially for those with medical conditions or taking other medications.

Support the show

Production and Content: Edward Delesky, MD & Nicole Aruffo, RN
Artwork: Olivia Pawlowski